Allergy Therapeutics (Allergy Therapeutics) LT-Debt-to-Total-Asset : 0.12 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Allergy Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Allergy Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.12.

Allergy Therapeutics's long-term debt to total assets ratio increased from Dec. 2022 (0.11) to Dec. 2023 (0.12). It may suggest that Allergy Therapeutics is progressively becoming more dependent on debt to grow their business.

Allergy Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Allergy Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics LT-Debt-to-Total-Asset Chart

Allergy Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.12

0.11

0.51

Allergy Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.09	0.11	0.11	0.51	0.12

Allergy Therapeutics LT-Debt-to-Total-Asset Calculation

Allergy Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )	/	Total Assets (A: Jun. 2023 )
	=	43.164	/	84.304
	=	0.51

Allergy Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	10.253	/	87.439
	=	0.12

Allergy Therapeutics (OTCPK:AGYTF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Allergy Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Allergy Therapeutics (Allergy Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (OTCPK:AGYTF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

AGY:UK HHU:Germany

Address

Dominion Way, Worthing, West Sussex, GBR, BN14 8SA

Website

https://www.allergytherapeutics.com

Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.